Business Context and Reporting Period
Company: Materialise NV (Belgium)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Materialise is a leading provider of additive manufacturing (3D printing) software, medical software tools, and sophisticated 3D printing services. The company operates through three primary segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. As of December 31, 2024, the company employed 2,514 full-time equivalents.
Key Financial Metrics (2024)
| Metric | 2024 (€ millions) | 2023 (€ millions) | Change |
|---|---|---|---|
| Revenue | 266.8 | 256.1 | +4.2% |
| Net Profit | 13.4 | 6.7 | +99.9% |
| Adjusted EBIT | 9.7 | 9.9 | -2.0% |
| Adjusted EBITDA | 31.5 | 31.4 | +0.3% |
| Operating Cash Flow | 31.5 | 20.2 | +56.1% |
| Cash & Equivalents | 102.3 | 127.6 | -19.8% |
| Total Debt | 41.3 | 64.4 | -35.9% |
Note: All figures in Euros (€). Adjusted EBIT and Adjusted EBITDA are non-IFRS measures.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 4.2% to €266.8 million. Growth was driven by the Materialise Medical segment (+14.8%), which offset declines in the Software (-1.2%) and Manufacturing (-3.4%) segments.
- Profitability Surge: Net profit nearly doubled to €13.4 million, primarily due to a significant improvement in "Net other operating income" (turning from a €6.5M expense in 2023 to a €4.2M income in 2024) and increased financial income.
- Segment Performance:
- Medical: Adjusted EBITDA margin expanded to 30.6% (from 26.2%) due to revenue growth and cost control.
- Software: Adjusted EBITDA margin contracted to 12.7% (from 16.8%) due to continued investment in R&D and the transition to cloud-based subscription models.
- Manufacturing: Adjusted EBITDA margin dropped significantly to 1.6% (from 6.8%) due to unfavorable market conditions and investments in growth lines.
- Debt Reduction: Total loans and borrowings decreased by €23.1 million to €41.3 million, driven by the full repayment of a €28 million acquisition loan in October 2024.
- Acquisition: Acquired FEops NV in July 2024 for €2.985 million to expand AI-driven simulation capabilities in the cardiovascular market.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Strategy: The company is transitioning its Software segment from perpetual licenses to cloud-based SaaS models, which may impact short-term revenue recognition but is viewed as essential for long-term growth.
- Investment Focus: Continued investment in R&D (€44.4M in 2024, up 16.5%) and capital expenditures (€26.4M in 2024, primarily for production capacity expansion in Germany).
- Ukraine Operations: Operations in Kyiv (over 400 collaborators) remain subject to uncertainty due to the armed conflict. While currently operational, the company notes potential for future disruption or increased costs.
Key Risks & Contingencies:
- Internal Control Material Weakness: The company identified a material weakness in internal controls over financial reporting related to risk assessment and monitoring processes during the migration to new information systems. The auditor issued an adverse opinion on the effectiveness of internal controls, though the financial statements themselves received an unqualified opinion.
- Geopolitical Instability: Ongoing conflicts in Ukraine, Israel, and the Middle East, as well as US-China tensions, pose risks to operations, supply chains, and demand.
- Regulatory Environment: The Medical segment faces rigorous regulation (FDA, EU MDR). Delays in approvals or enforcement actions could materially impact the business.
- Competition: Intense competition in software (open-source, OEM bundling) and manufacturing (customers bringing production in-house) threatens market share.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for the identified material weakness in internal controls over financial reporting.
- Software Transition Impact: Monitor the revenue mix shift from perpetual to subscription-based models in the Software segment and its effect on recurring revenue stability.
- Manufacturing Margins: Assess the sustainability of the Materialise Manufacturing segment's profitability given the sharp decline in Adjusted EBITDA margin to 1.6%.
- Ukraine Exposure: Review updates on the operational status and cost implications of the Kyiv office and the potential for workforce displacement.
- Customer Concentration: Note that one customer accounted for >10% of total revenue (€50.5M) in 2024, all within the Medical segment.